[6] Planchard D. et al,J Thorac Oncol. 2022 Jan;17(1):103-115 [7] Meng P, Koopman B, Kok K, et al. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osime...
The purpose of this article is to evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic metastaticdifferentiated thyroid cancer (DTC) with a BRAF p.V6...
max-age=0, private, must-revalidate - content-type: application/json; charset=utf-8 - etag: W/"daaa56b952e51b9f9877e9003e8e0a82" - x-request-id: 139e9fbe-f6d7-44ca-b561-65a52afcf0e7 2023-03-28T13:03:03.160Z: Sending "Partners" GraphQL request: mutation appUpdate($apiKey: St...
The ΔE mutation did not affect thymic cellularity or the total number of γδ T cells (Fig. 6b and Supplementary Fig. 4f); however, it did reduce both the frequency and number of Vγ1Vδ6.3 expressing NKγδT cells (Fig. 6b), suggesting that E protein binding downstream of Trav15d...
BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012 Dec;97(12): 4559-70.Li C, Lee KC, Schneider EB, Zeiger MA 2012 BRAFV600E mutation and its association with clinico- pathological features of ...
A particularly bad prognosis might be expected for colorectal tumors with the unique molecular subtype BRAF V600E mutation. With the development of precision therapy, the advent of molecularly targeted therapies and immune checkpoint inhibitors has improved the outcome of intermediate to advanced ...
Roughly 8% of mCRC tumors harbor a BRAF(V600E) mutation... Jean-Philippe Coppe,Denise P. Muoz,Chloe E. Atreya,... - Cancer research 被引量: 0发表: 2024年 BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist Background: This article is co-authored ...
BRAF mutation in sporadic colorectal cancer and Lynch syndrome A, von Knebel Doeberitz M, Kloor M (2013) BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int... A Thiel,M Heinonen,J Kantonen,... - 《Virchows Archiv European Journal of...
A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Mol Cancer Ther 2009; 8: B88. 36. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets...
解放军总医院胡毅教授于当地时间2023年10月21日 08:35-08:40在转移性NSCLC专场以线上形式作了题为“Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic...